Metraipolis › archive › dc_486f62a43fca
Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh — Europe PMC PMID:39854407
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39854407
- DOI
- 10.1371/journal.pone.0312174
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T13:45:58.617Z
- SHA-256 of the archived text
559448a01e7be891a05878c05154daf6bdad5dfdb7b83fa89637cc7968f153bc- Stable URL of this page
https://metraipolis.com/documento/dc_486f62a43fca
How to cite
Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh — Europe PMC PMID:39854407 — Europe PMC (en), https://europepmc.org/article/MED/39854407 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_486f62a43fca (Metraipolis archive dc_486f62a43fca, sha256 559448a01e7be891a05878c05154daf6bdad5dfdb7b83fa89637cc7968f153bc)
BibTeX
@misc{dc486f62a43fca,
title = {Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh — Europe PMC PMID:39854407},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39854407},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_486f62a43fca; sha256 559448a01e7be891a05878c05154daf6bdad5dfdb7b83fa89637cc7968f153bc},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39854407. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Juvenile Idiopathic arthritis (JIA) is one of the most common chronic diseases in children. It still remains a challenge to treat refractory poly-articular course JIA patients, especially in Bangladesh, where patients from low socio-economic backgrounds are unable to manage biological agents. Tofacitinib is one of the alternative options to biological agents, which can be taken orally and is cost effective. The purpose of this prospective observational study was to evaluate the efficacy of tofacitinib in the treatment of refractory poly-articular course JIA cases. Materials and methods: This study was carried out in the Department of Pediatrics, Bangabandhu Sheikh Mujib Medical University (BSMMU). A total number of 50 refractory polyarticular course JIA patients received JAK-2 inhibitor, tofacitinib along with other drugs according to the recommended doses. The disease activity level was measured by Juvenile Arthritis Disease Activity Score-27 (JADAS-27). All the cases were assessed at baseline, 6th, 12th and52nd week of tofacitinib therapy. The relevant statistical tests were applied for data analysis. Results: After treating the refractory cases with tofacitinib, arthritis subsided, and laboratory parameters improved in all the cases. Overall JADAS-27 score improvement was 40.67%, 56.38% and 96% at 6th, 12th and 52nd week of follow-up respectively. It was also possible to taper the dose of steroid gradually and stopped it by 24 weeks. Tofacitinib was well tolerated with minimum side effects. Conclusions: Tofacitinib was effective to all the children with poly-articular course JIA. It was well tolerated and had very few tolerable adverse effects. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-01-24). Identificativi: PMID 39854407 · PMCID PMC11759992 · DOI 10.1371/journal.pone.0312174. Descrittori MeSH principali: Piperidines; Pyrimidines; Pyrroles; Protein Kinase Inhibitors; Arthritis, Juvenile. Pagina: https://europepmc.org/article/MED/39854407 — https://doi.org/10.1371/journal.pone.0312174. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T12:00:49.460Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.